Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West

V. H.F. Lee, J. Seong, S. M. Yoon, T. C.L. Wong, B. Wang, J. L. Zhang, C. L. Chiang, P. P.Y. Ho, L. A. Dawson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is a common malignancy worldwide, although its aetiologies vary significantly between the East and the West. About a half of HCC cases present with advanced unresectable HCC at the time of diagnosis, leading to a worse prognosis. Over the past 20 years, the treatment paradigm for advanced unresectable HCC has shifted from an entirely palliative approach to a multidisciplinary treatment, with continuous reassessment and possible repeat treatment attributed to the advent of novel and improved local, regional and systemic therapeutic options, contributed by both the East and the West. An individualised treatment plan should be determined for each patient, as there can be substantial differences in the decision-making and treatment response to the same treatment for different patients and different patient populations. This review provides a summary of the recent advances in management and compares Eastern and Western strategies for HCC.

Original languageEnglish
Pages (from-to)560-569
Number of pages10
JournalClinical Oncology
Volume31
Issue number8
DOIs
Publication statusPublished - 2019 Aug

Fingerprint

Hepatocellular Carcinoma
Therapeutics
Decision Making
Population
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Lee, V. H.F. ; Seong, J. ; Yoon, S. M. ; Wong, T. C.L. ; Wang, B. ; Zhang, J. L. ; Chiang, C. L. ; Ho, P. P.Y. ; Dawson, L. A. / Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West. In: Clinical Oncology. 2019 ; Vol. 31, No. 8. pp. 560-569.
@article{fb36d78d51944e36b507b5218b6dafe8,
title = "Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West",
abstract = "Hepatocellular carcinoma (HCC) is a common malignancy worldwide, although its aetiologies vary significantly between the East and the West. About a half of HCC cases present with advanced unresectable HCC at the time of diagnosis, leading to a worse prognosis. Over the past 20 years, the treatment paradigm for advanced unresectable HCC has shifted from an entirely palliative approach to a multidisciplinary treatment, with continuous reassessment and possible repeat treatment attributed to the advent of novel and improved local, regional and systemic therapeutic options, contributed by both the East and the West. An individualised treatment plan should be determined for each patient, as there can be substantial differences in the decision-making and treatment response to the same treatment for different patients and different patient populations. This review provides a summary of the recent advances in management and compares Eastern and Western strategies for HCC.",
author = "Lee, {V. H.F.} and J. Seong and Yoon, {S. M.} and Wong, {T. C.L.} and B. Wang and Zhang, {J. L.} and Chiang, {C. L.} and Ho, {P. P.Y.} and Dawson, {L. A.}",
year = "2019",
month = "8",
doi = "10.1016/j.clon.2019.06.002",
language = "English",
volume = "31",
pages = "560--569",
journal = "Clinical Oncology",
issn = "0936-6555",
publisher = "W.B. Saunders Ltd",
number = "8",

}

Lee, VHF, Seong, J, Yoon, SM, Wong, TCL, Wang, B, Zhang, JL, Chiang, CL, Ho, PPY & Dawson, LA 2019, 'Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West', Clinical Oncology, vol. 31, no. 8, pp. 560-569. https://doi.org/10.1016/j.clon.2019.06.002

Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West. / Lee, V. H.F.; Seong, J.; Yoon, S. M.; Wong, T. C.L.; Wang, B.; Zhang, J. L.; Chiang, C. L.; Ho, P. P.Y.; Dawson, L. A.

In: Clinical Oncology, Vol. 31, No. 8, 08.2019, p. 560-569.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West

AU - Lee, V. H.F.

AU - Seong, J.

AU - Yoon, S. M.

AU - Wong, T. C.L.

AU - Wang, B.

AU - Zhang, J. L.

AU - Chiang, C. L.

AU - Ho, P. P.Y.

AU - Dawson, L. A.

PY - 2019/8

Y1 - 2019/8

N2 - Hepatocellular carcinoma (HCC) is a common malignancy worldwide, although its aetiologies vary significantly between the East and the West. About a half of HCC cases present with advanced unresectable HCC at the time of diagnosis, leading to a worse prognosis. Over the past 20 years, the treatment paradigm for advanced unresectable HCC has shifted from an entirely palliative approach to a multidisciplinary treatment, with continuous reassessment and possible repeat treatment attributed to the advent of novel and improved local, regional and systemic therapeutic options, contributed by both the East and the West. An individualised treatment plan should be determined for each patient, as there can be substantial differences in the decision-making and treatment response to the same treatment for different patients and different patient populations. This review provides a summary of the recent advances in management and compares Eastern and Western strategies for HCC.

AB - Hepatocellular carcinoma (HCC) is a common malignancy worldwide, although its aetiologies vary significantly between the East and the West. About a half of HCC cases present with advanced unresectable HCC at the time of diagnosis, leading to a worse prognosis. Over the past 20 years, the treatment paradigm for advanced unresectable HCC has shifted from an entirely palliative approach to a multidisciplinary treatment, with continuous reassessment and possible repeat treatment attributed to the advent of novel and improved local, regional and systemic therapeutic options, contributed by both the East and the West. An individualised treatment plan should be determined for each patient, as there can be substantial differences in the decision-making and treatment response to the same treatment for different patients and different patient populations. This review provides a summary of the recent advances in management and compares Eastern and Western strategies for HCC.

UR - http://www.scopus.com/inward/record.url?scp=85067346432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067346432&partnerID=8YFLogxK

U2 - 10.1016/j.clon.2019.06.002

DO - 10.1016/j.clon.2019.06.002

M3 - Article

C2 - 31279433

AN - SCOPUS:85067346432

VL - 31

SP - 560

EP - 569

JO - Clinical Oncology

JF - Clinical Oncology

SN - 0936-6555

IS - 8

ER -